The collaboration is aimed at generating novel multi-antigen specific antibody therapeutics.. As per the terms of the agreement, AnaptysBio is expected to be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) technology platform.
Reportedly, Antibodies generated by AnaptysBio will be developed and commercialised by VLST. AnaptysBio has received an upfront payment to initiate the collaboration and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.
Tom Smart, chairman and CEO at AnaptysBio, said: "A key objective of this collaboration is to leverage the ability of AnaptysBio's SHM-Platform to select antibodies that bind specifically to multiple target antigens of interest. Antibodies that bind specifically to multiple antigens are an area of increasing interest to the industry and one of the most exciting areas for novel therapeutic antibody development.
"We anticipate entering more collaborations because of growing interest in our platform's ability to naturally evolve antibodies to meet challenging design goals and simultaneously select across multiple parameters for those with the desired properties, such as multi-antigen binding specificity."